According to some studies, FLT3-ITD mutations enhance leukemia cell chemotaxis toward CXCL12, thus providing a drug resistance mechanism underlying the poor effect of FLT3-ITD antagonists14,26. This evidence concerns the gene CXCL12 and leukemia.